Index

Action Program on Essential Drugs, 18,20,141-142
Adverse reactions section of label, 5,43-44
Advertising, pharmaceutical codes of conduct and, 131-139
detail men, 111
in developing countries, 110-112
fairness and balance test, 95
medical journals, 111-112
over-the-counter drugs, 11, 95-96
prescription drugs, 11,95-96
reminder advertisements, 18, 137
WHO ethical criteria, 16-17, 133-135
Alcohol as an ingredient, 41
AMA. See American Medical Association
AMA Drug Evaluations, 32, 106
American Hospital Formulary Service, 106
American Law Institute, 13, 118
American Medical Association, 32, 106
Anabolic steroid study, 156-157
Antibiotics: The Wrong Drugs for Diarrhoea, 151
Antidepressant drugs, 152
Antidiarrhea drugs, 151-152, 155-156
Antitrust laws, 120-121
APED. See Action program on Essential Drugs
Argentina, drug advertising, 111
Association of the British Pharmaceutical Industry, 146
Bad Medicine: The Prescription Drug Industry in the Third World, 42
Balasubramaniam, K., 150
Batch certificates, 19, 145
Bitter Facts About Drugs, 151
Boycotts, 13, 117, 123, 131
Brazil
drug advertising, 111
drug labeling, 164
drug registration, 163-164
obtaining product labels, 28-29
package inserts, 29
sample product selection, 28
selection for study, 27
Bristol-Myers Squibb Co., 115
BUKO, 152
Bush, George, economic sanctions against Iraq, 122
Cancer treatment, off-label prescribing and, 105-106
Carter, Jimmy, freezing of Iranian assets, 122
Certificates for pharmaceutical products, 19
Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce, 19,20, 142-146
Chetley, Andrew, 151
Chloramphenicol study, 155
CIOMS. See Council for International Organizations of Medical Sciences
Clayton Act, 120
Cleared for Export, 151
Clinical pharmacology section of label, 4,40
Clioquinol study, 155-156
Code of Conduct for Companies Operating in South Africa, 15
Code of Conduct for Translational Corporations, 15-16,23,24, 128, 130-131
Code of Pharmaceutical Marketing Practices, 9, 17-18
criticisms of, 138-139
description, 135-136
implementation, 136-137
reporting and resolution of violations, 137-138
Codes of conduct, 15-18, 23-24
under international law, 128-135
Collaborating Center for Monitoring of Adverse Drug Reactions, 20
Collaborating Centre for International Drug Monitoring, 146-147
Combination drugs, 103-104
Comity principle of international law, 118-119
Consumer Action and Resource Kit on Pharmaceuticals, 149
Consumer Alerts, 150
Consumer groups
health advocates, 149-153
IFPMA ethical criteria and, 134-135
infant formula and, 132
international programs and, 21
Consumer Interpol, 149-150
Contraindications section of label, 5, 4243
Council for International Organizations of Medical Sciences, 24, 135

Data Sheet Compendium, 146
DEACs. See Drug Export Act countries
Description section of label, 4, 440
DESI. See Drug Efficacy Study Implementation
Detail men, 111
Dictionaire Vidal, 146
Dingell, John, 2
DMP. See Drug Management and Policies Division, World Health Organization
Dosage and administrative section of label, 5-6, 44
Drug Diplomacy: Decoding the Conduct of a Multinational Pharmaceutical Company, 151
Drug Disinformation: What British and Multinational Drug Companies Tell Doctors About Their Products, At Home and Abroad, 152
Drug Efficacy Study Implementation, 95
new drug review, 103-104
Drug Export Act countries, 45, 49
Drug Export Act of 1986, 2, 6-7, 45, 96-98
Drug Facts and Comparisons, 32

Drug Information for the Health Care Professional, 32, 106
Drug Labeling studies, 155-162
Drug Management and Policies Division, World Health Organization, 18-19, 142, 146
The Drugging of the Americas, 158, 159, 161
Drugs and Primary Health Care, 151
Drugs and World Health, 152
Drugs Used in Anesthesia, 146
Drugs Used in Mycobacterial Diseases, 146
Drugs Used in Parasitic Diseases, 146

EAA. See Export Administration Act
Economic sanctions, 121-123
Effects principle of international law, 13, 14, 117-118, 125

Enforcement Report, 148
The Essential Drugs Monitor, 18, 142
“Ethical and Scientific Criteria for Pharmaceutical Advertising,” 16, 133
“Ethical Criteria for Medicinal Drug Promotion,” 16-17, 18, 24, 133-135
European Community, codes of conduct, 15
Expert Advisory Panel on Drug Evaluation, 7, 49
Expert Review Group
first review, 31-32
medical importance standard, 30
original label examination, 29
scoring review, 36

Export Administration Act, 13, 121-123
Exported drugs
FDCA and, 11
labeling, 11, 96-98
tropical disease drugs, 12, 98
unapproved drugs, 11, 96

Extraterritorial jurisdiction
antitrust laws, 120-121
health and safety of foreign nationals and, 14-15, 125-126
international law principles, 12-13, 117-119, 125-126
U.S. laws allowing, 13-14

Fairness and balance test, 95
FCPA. See Foreign Corrupt Practices Act
FDA. See Food and Drug Administration
FDA Consumer Information, 148
FDA Medical Bulletin, 148
FDCA. See Food, Drug, and Cosmetic Act

   See BUKO

Federal Register, 148

Federal Trade Commission, 23

Federal Trade Commission Act, 120

Food, Drug, and Cosmetic Act, 9, 91
   export of pharmaceuticals, 11
   1962 amendments, 95

Food and Drug Administration
   cooperation with WHO programs, 148
   exported pharmaceuticals labeling, 11
   extraterritorial jurisdiction, 12-15
   FDCA and, 91
   international activities, 20, 143, 147-148
   labeling standard, 3
   tropical disease drug export, 12
   unapproved drug export, 11
   unlabeled indications, 104
   U.S. drug labeling, 9-11

Foreign Corrupt Practices Act, 13-14, 22-23, 123-125, 126

Foreign relations law, 118-120

France
   drug approval process, 107
   drug efficacy standards, 107

GAIT. See General Agreement on Tariffs and Trade

General Accounting Office
   export of unapproved drugs, 96
   off-label prescribing study, 105

General Agreement on Tariffs and Trade, 15

Germany
   drug approval process, 107
   labeling, 107

Global Marketing of Pharmaceuticals: Prescription for Disaster, 150

“Good Practices in the Manufacture and Quality Control of Drugs,” 142

Guidelines for Multinational Corporations, 15, 128

“Guiding Principles for Small National Authorities,” 20, 148

HAI. See Health Action International

HAI News, 151

“The Hartog and Schulte-Sasse Study,” 152, 161

Harvard Medical School, 153

Health Action International
   code of conduct, 150-151
   description, 21, 149, 150
   ethical criteria critique, 151
   IFPMA critique, 151

Health Horizons, 137

Hoechst, 152

House Subcommittee on Health and the Environment of the Committee on Energy and Commerce, 98

IBFAN. See International Baby Food Action Network

IEEPA. See International Emergency Economic Powers Act

IFM. See International Association of Infant Food Manufacturers

IFPMA. See International Federation of Pharmaceutical Manufacturers Associations

ILO. See International Labour Office

India
   multinational corporations and, 116
   WHO collaborating center, 146

Indications section of label, 4-5, 41-42

Indonesia, multinational corporations and, 116

IND. See Investigational new drug exemption

Inert ingredients, 41

Infant formula, 16, 23-24, 125, 131-133

Ingredients section of label, 4, 40-41

INRUD. See International Network for the Rational Use of Drugs

INRUD News, 153

Institutional Review Boards, 100

Insult or Injury? An Enquiry into the Marketing and Advertising of British Food and Drug Products in the Third World, 151

Interfaith Center on Corporate Responsibility, 131

International Affairs Staff, Food and Drug Administration, 147

International Association of Infant Food Manufacturers, 16, 132

International Baby Food Action Network, 131, 132

International Chamber of Commerce, 15, 128

International Code of Marketing of Breast-Milk Substitutes, 16, 23-24, 128

International Conference of Drug Regulatory Authorities, 20
International Federation of Pharmaceutical Manufacturers Associations
codes of conduct, 16, 17-18, 24, 128, 133, 135-139
drug advertising, 111
International Federation of Pharmaceutical Manufacturers Associations
codes of conduct, 16, 17-18, 24, 128, 133, 135-139
drug advertising, 111
product promotion guidelines, 9
International Labour Office, 15, 128
International law
codes of conduct, 15-18, 128-135
foreign relations law, 118-120
multinational corporations, 116-120
principles, 12-13, 117-119, 125-126
rule of reasonableness and, 119
International Network for the Rational Use of Drugs, 21, 148, 153
International Non-proprietary Name, 136
International Organization of Consumers Unions, 21, 132, 149-150
labeling studies, 155-162
International Pharmaceutical Federation, 49
International programs for labeling improvement consumer groups, 21, 149-153
FDA international activities, 20, 143, 147-148
prescribing information distribution, 7, 18-19, 49, 146
safety and efficacy information access, 19-20
USAID programs, 20-21, 145-146, 148-149
WHO Certification Scheme, 19, 20, 142-146
“International Regulation of the Supply and Use of Pharmaceuticals,” 152
International Union of pharmacology, 49
International Workshop on Consumer Health and Drug Information and Education, 149
Investigational new drug exemptions application, 99-100
exemption for clinical trials in human beings, 96
IOCU. See International Organization of Consumers Unions
IRBs. See Institutional Review Boards
Italy, bribery of officials, 124
Japan
bribery of officials, 123-124
inert ingredients database, 41
Journal of the American Medical Association, 106
Kennedy, Edward, 2
Kenya
drug registration and labeling, 164-165
obtaining product labels, 29
package inserts, 29
sample product selection, 28
selection for study, 27
Labeling changes, prescription drugs, 94
Laws. See specific laws and regulations by name;
U.S. drug labeling laws and regulations
Lee. See Silverman, Lydecker, and Lee, labeling studies
Lockheed Corp., 123-124
Lydecker. See Silverman, Lydecker, and Lee, labeling studies
MaLAM, See Medical Lobby for Appropriate Marketing
Management Sciences for Health, 153
Manual for Rural Health Workers: Diagnosis and Treatment with Essential Drugs, 18, 142
Marketing. See Advertising
Medawar, Charles, 152
Medical Bulletin, 20, 147
Medical Devices and Radiological Health, 148
Medical importance standard, 3, 30-31, 32, 35, 40-49, 104
Medical Lobby for Appropriate Marketing, 21, 137-139, 152-153
Medicines Control Agency, 107
Merck & Co., 115
MNCs. See Multinational corporations
Model Guide to Good Prescribing, 18, 142
“Model List of Essential Drugs,” 7, 49, 142, 161
Model Prescribing Information, 142
Moscow Olympics boycott, 123
Multinational corporations
bribery of foreign officials, 13-14, 123-125, 126
codes of conduct and, 15, 114, 128-139
description, 113-114
drug advertising, 111
drug labeling influences, 8
extraterritorial jurisdiction and, 120-126
growth of, 114-115
health and safety of foreign nationals, 14-15, 125-126
host country laws, 106
international law, 116-120
joint venture arrangements, 115
labeling studies, 155-162
legal control, 8-9
markets, 7-8
proprietary products licensing to foreign compa-
nies, 116
structure, 8, 115-116
trade embargoes and economic sanctions, 121-123
U.N. standards for, 9, 130-131

NAS. See National Academy of Sciences
National Academy of Sciences, new drug review,
103-104
Nationality principle of international law, 12, 13,
117, 125-126
NDA. See New Drug Application
Nestle Corp., 131-133
Nestle Infant Formula Audit Commission, 132
New Drug Applications, 91,99, 101-102
over-the-counter drugs, 95
New drug approval
clinical trials, 100-101
definition of "new," 98-99
Investigational New Drug exemption, 99-100
NDA review, 101-102
preclinical research, 99
Nigeria, labeling study, 160-161

OECD. See Organization for Economic Co-operation
and Development
Off-label prescribing, 104-106
Office of International Affairs, U.S. Public Health
Service, 147
One Drug at a Time: A Report on the Limitation of
Fixed Ratio Combination Drugs, 152
Options for Congressional action, 21-24
Organization for Economic Co-operation and
Development, 14, 15, 124-125, 128
Osifo, Nosakhare Guy, 160-161

OTA Labeling evaluation process
analysis and final results, 37
corporate response evaluation, 32-34
Expert Review Group reviews, 31-32,36
interim and revised overall scores, 37
medical importance standard, 30-31, 32, 35, 40-49
preliminary screening, 31
 provision of scoring sheets to companies, 34-36

queries to companies, 32
scoring of labels, 34-36,4049
summary sheets for additional responses, 36-37

OTC. See Over-the-counter drugs
Over-the-counter drugs
advertising, 11,95-96
classes, 95
labeling, 10-11,94-95
package inserts, 29

Overdosage section of label, 6,44
Package inserts, 10,29-30,92-93, 107
in developing countries, 109-110
Package labels for prescription drugs, 92-93
PAHO. See Pan American Health Organization
Pan American Health Organization, 147, 148
Panama
drug registration and labeling, 165-166
obtaining product labels, 28-29
package inserts, 29
prescribing guides, 3
sample product selection, 28
selection for study, 27
PDR. See Physicians’ Desk Reference
Peddling Placebos: An Analysis of Cough and Cold
Remedies, 151
Pediatric drug prescribing, 105-106
Pfizer, Inc., 115
Pharma-Brief, 152
Pharmaceutical labeling studies, 155-162
Pharmaceutical Manufacturers Association, 7,28,45,
135

Physicians’ Desk Reference, 31, 146
Physicians’ Desk Reference for Nonprescription
Drugs, 31
Pills, Profits and Politics, 158
PMA. See Pharmaceutical Manufacturers Association
Policies and Strategies on Drug Pricing Regulations:
International Experiences, 150
Policy Options in Pharmaceutical Patents for
Developing Asian Countries, 150
Post-marketing surveillance, 102-103
Power and Dependence, 152
Precautions section of label, 5,43
Prescribing guides, 3, 30
in developing countries, 110
Prescription drugs
advertising, 11,95-96
labeling changes, 94
labels, 10,92-93
package inserts, 29,92-93
standards of evidence, 94
*Prescription for Death: The Drugging of the Third World*, 159, 162
*Problem Drugs*, 151
Product documents, 107-108
*Promoting Health or Pushing Drugs? A Critical Examination of Marketing of Pharmaceuticals*, 151
Protective principle of international law, 117
*The Provision and Use of Drugs in Developing Countries*, 151
Qualitative results of OTA survey, 3940,54-91
Quantitative results of OTA survey
category of information analysis, 4-6
country analysis, 6,44
labeling category analysis, 40-44
other industrialized country comparison, 6-7,45-49
overall analysis, 40
WHO model prescribing information, 7,49
Queries to companies, 32-34
*A Question of Control*, 151
*The Rational Use of Drugs: A Universal Concept*, 150
Reagan, Ronald, Breast-Milk Substitutes code and, 133
Reminder advertisements, 18, 137
Reporting requirements, new drugs, 102-103
Rhodesia, economic sanctions against, 123
Rule of reasonableness, 119
Sample selection, OTA Survey
country identification, 28
country selection, 27-28
label translations, 30
sample products, 28-30
Schulte-Sasse. See “The Hartog and Schulte-Sasse Study”
*SCRIP World Pharmaceutical News*, 137
Searle Pharmaceuticals, 151-152
export of unapproved drugs, 96
Sherman Act, 120-121
Silverman, Lydecker, and Lee, labeling studies, 42, 158-160
Social Audit, 151-152
labeling studies, 157-158
Statements of licensing status, 19, 145
Survey, OTA
category of information analysis, 4-6
country analysis, 6,44
country analysis, 6,445
labeling evaluation process, 30-37
other industrialized country comparison, 6-7,45-49
process, 2-3,27-37
qualitative results, 39-40,54-91
quantitative results, 40-54
results, 3-7
sample selection, 27-30
scoring categories, 3-6, 34
WHO model prescribing information and, 7,49
Syntex Corp., 116
*Ten Year Report on the IFPMA Code*, 137
Territorial principle of international law, 12-13, 117
Thailand
drug registration and labeling, 166-167
obtaining product labels, 29
package inserts, 29-30
sample product selection, 28
selection for study, 28
Third International Conference of Drug Regulatory Authorities, 143
Trade embargoes, 13, 117, 121-123
Translation of foreign language labeling, 30
Translational Code. See Code of Conduct for Transnational Corporations
Treaties, codes of conduct and, 129
Tropical disease drugs, 98
export, 12
U.N. Centre on Translational Corporations, 130-131
labeling studies, 160
U.N. Conference on Trade and Development Code of Conduct on Restrictive Business Practices, 15, 128
U.N. Council for Trade and Development, 133
Unapproved drugs, 96-98
export, 11,96-98
United Kingdom
drug approval process, 107
sales representatives, 111

United Nations. See also specific divisions by name
codes of conduct, 15-16, 23, 24, 128, 130-131
standards for MNCs, 9
United Nations International Court of Justice, 116
United Nations Participation Act, 123
United States Pharmacopeial Convention, 106
U.S. Agency for International Development, 19
cooperative agreement with U.S. Pharmacopoeia, 20-21, 148-149
WHO and, 20, 145-146, 148
U.S. Department of State, 147-148
U.S. drug labeling laws and regulations. See also specific laws and regulations by name
DESI review, 103-104
exported drugs, 96-98
new drug approval, 98-102
off-label prescribing, 104-106
over-the-counter drugs, 94-96
post-marketing surveillance, 102-103
prescription drugs, 92-94
U.S. Pharmacopoeia, 148-149
agreement with USAID, 20-21
U.S. Public Health Service, 147
U.S. Securities and Exchange Commission, 123
U.S. Senate Committee on Labor and Human Resources, 105
U.S. Trade Representative, 147
USAID. See U.S. Agency for International Development

USP DI. See Drug Information for the Health Care Professional

Veterinary Medicine, 148

Warnings section of label, 5,43
Waxman, Henry, 2
WHO. See World Health Organization
WHO Drug Information, 20, 146
WHO Model Prescribing Information, 18-19, 146
WHO Pharmaceutical Newsletter, 20, 146
World Federation of Proprietary Medicine Manufacturers, 49
World Health Assembly, 135, 143
World Health Organization
Action Program on Essential Drugs, 18,20, 141-142
Certification Scheme, 19,20, 142-146
codes of conduct, 16, 128
collaborating centers, 20, 146-147
Division of Drug Management and Policies, 18-19, 142, 146
drug advertising, 111
ethical criteria for drug promotion, 16-17, 24
Expert Advisory Panel on Drug Evaluation, 7,49
FDA and, 20
infant formula hearings, 125
prescribing information, 7, 18-19,49, 146
The Wrong Kind of Medicine?, 152

Yudkin, J. S., 157